Arterial blood clots may represent a hidden threat that kills more cancer patients than the widely recognized venous clots that dominate medical attention and prevention protocols. This emerging recognition could reshape how oncologists monitor and protect their patients from cardiovascular complications during treatment. The pathophysiology centers on three convergent mechanisms: direct injury to arterial walls, hypercoagulable blood chemistry, and excessive platelet activation triggered by tumor cells themselves. Specific chemotherapy agents pose distinct thrombotic risks, with platinum compounds like cisplatin and oxaliplatin, gemcitabine, and taxanes creating particularly hazardous conditions. Newer targeted therapies, including tyrosine kinase inhibitors, add another layer of arterial risk that wasn't anticipated when these precision medicines entered clinical practice. Lung and pancreatic cancers emerge as the highest-risk malignancies for arterial events, likely due to their aggressive tumor biology and propensity for systemic inflammation. Patient age and cancer staging amplify these baseline risks substantially. This analysis represents a significant shift from the traditional focus on venous thromboembolism in oncology. While venous clots receive extensive preventive attention through guidelines and prophylaxis protocols, arterial events may actually pose greater mortality risk due to their tendency to cause strokes and heart attacks. The complex interplay between tumor microenvironment factors and treatment-induced vascular injury suggests that current risk stratification models may be inadequately protecting patients from cardiovascular death during cancer therapy.